The Center for Medicare and Medicaid Innovation (CMMI) has provided new updates on CMS’ planned initiatives to address prescription drug costs in a blog post from Director Liz Fowler..
CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”
As outlined in our prior analysis, the Inflation Reduction Act (IRA) included sweeping drug pricing reforms for the Medicare program and the Biden-Harris administration has made clear.
On February 14, 2023, the U.S. Department of Health and Human Services (HHS) published a report identifying three models that the Center for Medicare & Medicaid Services’ (CMS) Center.